Approval Replaces a Case-by-Case Access Route
The Food and Drug Administration has approved daraxonrasib, sold as Rasonque, for adults with metastatic pancreatic adenocarcinoma, making a drug that patients could previously obtain only through clinical trials or a compassionate use program available for prescribing by treating oncologists.